Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.

But the biotech company's guidance for the current year missed Wall Street's expectations. Biogen issued a full-year 2025 adjusted earnings outlook of $15.25 to $16.25 per share, which fell short ...